Frontiers in allergy最新文献

{"title":"Pathophysiological and molecular insights into allergic conjunctivitis: an expanding analysis of immunological endotypes.","authors":"Henry Velazquez-Soto, Lorenzo Islas-Vazquez, Marisa Cruz-Aguilar, Estefanía Castillo-Balcazar, Ana X Yhmoff-Sanchez, María C Jiménez-Martínez","doi":"10.3389/falgy.2026.1863898","DOIUrl":"10.3389/falgy.2026.1863898","url":null,"abstract":"<p><p>Allergic conjunctivitis (AC) is an ocular surface disease characterized by immune-mediated inflammation that can significantly impair quality of life. This review explores recent advances in understanding the immunological and molecular mechanisms underlying AC, highlighting local and systemic immune responses and their roles in disease pathogenesis and progression. Particular attention is given to the influence of genetic and epigenetic factors, which may contribute to individual susceptibility and variability in clinical presentation. Finally, this review discusses emerging evidence on clinical phenotypes and immunological endotypes in ocular allergy, emphasizing their relevance for the development of targeted, personalized, and precision therapies.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1863898"},"PeriodicalIF":3.4,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13337925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Chronic Angioedema Registry: what the first 2 years since the implementation of the global registry have taught us.","authors":"Thomas Buttgereit, Mathias Sulk, Jonathan A Bernstein, Alicja Kasperska-Zajac, Andreas Kleinheinz, Ankur Jindal, Anna Valerieva, Danny M Cohn, Henriette Farkas, Herberto Jose Chong-Neto, Ivan Cherrez-Ojeda, Ivan Markovic, Kanokvalai Kulthanan, Mohamed Abuzakouk, Moshe Ben-Shoshan, Murat Türk, Natasa Teovska Mitrevska, Noemi A Bara, Oscar Calderon Llosa, Philip H Li, Ramon Lleonart Bellfill, Renate Krüger, Riccardo Senter, Roman Hakl, Sabine Altrichter, Simon Francis Thomsen, Stefan Cimbollek, Nevenka Adjievska, Lasma Lapina, Jonny Peter","doi":"10.3389/falgy.2026.1799211","DOIUrl":"10.3389/falgy.2026.1799211","url":null,"abstract":"<p><strong>Background: </strong>The Chronic Angioedema Registry (CARE) is the first international, multicenter observational registry established to systematically collect clinical and patient-reported data from patients with recurrent angioedema of any type during routine clinical care. Here we report enrollment after 2 years of CARE, discuss challenges and present ideas to overcome them.</p><p><strong>Methods: </strong>Registry growth, recruitment yield, and distribution of angioedema diagnosis were analyzed descriptively as of December 12, 2025. Additionally, a structured web-based survey was conducted among physicians within the network of Angioedema Centers of Reference and Excellence to assess participation status, perceived barriers and facilitators, satisfaction, and communication preferences.</p><p><strong>Results: </strong>Since its inception in October 2023, CARE enrolled 550 patients across 23 centers in 18 countries [mean (range): 24 (0-302)/center, 31 (0-321)/country], achieving predefined milestones on schedule. Hereditary angioedema and mast cell-mediated angioedema were the most frequent diagnoses. The survey included 22 respondents from 18 countries, representing centers at different stages of participation. Administrative and organizational challenges, particularly ethics approval processes and limited staff resources, were identified as the main barriers. Overall satisfaction with CARE was high, increasing with advanced participation. Flexible handling of regulatory requirements, strong onboarding support, and training materials were perceived as key facilitators. Conferences, in-person meetings, and newsletters were the preferred communication channels.</p><p><strong>Discussion: </strong>CARE has rapidly evolved into a robust global real-world resource for recurrent angioedema. Addressing regulatory and organizational barriers and strengthening tailored support and communication strategies will be essential to sustain growth, enhance participation, and maximize its long-term scientific and clinical impact.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1799211"},"PeriodicalIF":3.4,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic immunologic effects of long-term dupilumab treatment in severe eosinophilic asthma beyond clinical outcomes.","authors":"Sabina Škrgat, Luka Kunej, Urška Bidovec-Stojkovič, Matevž Harlander, Saša Rink, Peter Korošec, Peter Kopač","doi":"10.3389/falgy.2026.1873964","DOIUrl":"10.3389/falgy.2026.1873964","url":null,"abstract":"<p><strong>Introduction: </strong>Dupilumab, an IL-4R<i>α</i> antagonist that blocks IL-4/IL-13 signalling, is used in severe eosinophilic asthma to improve clinical control and suppress type 2 inflammation.</p><p><strong>Methods: </strong>We evaluated the clinical and systemic immunologic effects of dupilumab, focusing on type 2 biomarkers, total and aeroallergen-specific IgE, and FcεRI (High affinity IgE receptor) - expressing cells. Thirty-three adults with severe eosinophilic asthma were enrolled and followed up for 12 months in two Slovenian centres. Clinical assessments, spirometry, FeNO (Fractional exhaled nitric oxide), ACT (Asthma Control Test) scores, complete blood counts, total IgE, aeroallergen-specific IgE, and FcεRI expression on basophils were measured at baseline and at 1.5, 3, 6, and 12 months.</p><p><strong>Results: </strong>Twenty-seven patients completed follow-up and were included in the final analysis. Dupilumab treatment resulted in significant improvement in ACT (<i>p</i> = 0.0221), FEV1 (<i>p</i> = 0.0139) and reduction in exacerbations requiring OCS (oral corticosteroid) (<i>p</i> < 0.0001). FeNO declined by 78 %, total IgE by 83%, and aeroallergen-specific IgE by 65% with consistent reductions across perennial and seasonal allergens. Circulating eosinophils increased transiently, whereas basophils increased by 39%.</p><p><strong>Conclusions: </strong>Dupilumab demonstrated sustained clinical improvement in patients with severe eosinophilic asthma, accompanied by broad immunologic modulation. Concurrent reductions in FeNO, total IgE, and aeroallergen-specific IgE indicate upstream inhibition of IL-4/IL-13-mediated inflammation, suggesting modulation of the underlying type 2 inflammatory network.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1873964"},"PeriodicalIF":3.4,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologic-assisted immunotherapy for pediatric food allergy: a systematic review.","authors":"Anthony Mayer","doi":"10.3389/falgy.2026.1781735","DOIUrl":"10.3389/falgy.2026.1781735","url":null,"abstract":"<p><strong>Background: </strong>Food allergies affect up to 8% of children and are a major cause of anaphylaxis, reduced quality of life, and healthcare use. Oral immunotherapy (OIT) can induce desensitization but is limited by adverse reactions, tolerability challenges, and variable long-term outcomes. Emerging biologic therapies- particularly omalizumab and dupilumab- may improve the safety and efficiency of desensitization when used alone or with immunotherapy.</p><p><strong>Objective: </strong>To systematically review evidence on biologic-assisted immunotherapy and alternative desensitization approaches in pediatric food allergy, focusing on efficacy, sustained unresponsiveness, safety, treatment efficiency, and clinical applicability.</p><p><strong>Methods: </strong>A systematic review following PRISMA 2020 guidelines was conducted using PubMed, with supplementary searches of Google Scholar and SciSpace (2015-2025), to identify interventional studies of biologic therapies, OIT, sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT), and combination approaches in children < 18 years with IgE-mediated food allergy. Studies were synthesized using a narrative qualitative approach. Desensitization was defined as increased tolerated dose during active therapy; reaction threshold as the dose provoking symptoms; sustained unresponsiveness (SU) as absence of symptoms after treatment cessation; and tolerance as durable long-term nonreactivity independent of therapy. Risk of bias for randomized trials was assessed using the Cochrane Risk of Bias 2 (RoB2) tool.</p><p><strong>Results: </strong>Of 505 records, 17 studies met inclusion criteria. Omalizumab-assisted OIT demonstrated higher desensitization rates (approximately 67%-85%) and fewer adverse events compared with OIT alone (approximately 30%-40%), though effect sizes varied. Dupilumab showed modest improvements in tolerability with smaller effects on desensitization. Omalizumab monotherapy increased reaction thresholds across multiple allergens. SLIT and EPIT demonstrated favorable safety with moderate efficacy, particularly in younger children.</p><p><strong>Conclusion: </strong>Evidence suggests biologic-assisted immunotherapy- particularly omalizumab with OIT- may improve desensitization and safety in pediatric food allergy, though findings are limited by heterogeneity, sample size, and risk of bias. Larger trials are needed to confirm long-term durability, optimize protocols, and assess cost-effectiveness. SLIT and EPIT may offer safer alternatives for selected high-risk populations.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1781735"},"PeriodicalIF":3.4,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving prescriber confidence in COX-2 inhibitor use for aspirin-exacerbated respiratory disease: impact of a standard operating procedure.","authors":"Emily Hocknell, Peta-Lee Sacks, Ulka Vamadevan, Claire Hopkins","doi":"10.3389/falgy.2026.1854011","DOIUrl":"10.3389/falgy.2026.1854011","url":null,"abstract":"<p><strong>Introduction: </strong>Aspirin-exacerbated respiratory disease (AERD) presents a challenge in perioperative pain management. Many prescribers are uncertain about COX-2 inhibitor safety, leading to inconsistent prescribing practices and suboptimal analgesia in this group of patients. The aim of this small, single-centre study was to assess healthcare practitioners' confidence in prescribing analgesia for AERD patients and evaluate the impact of a standard operating procedure (SOP) on prescribing practices.</p><p><strong>Material and methods: </strong>An initial survey assessed practitioners' confidence in prescribing analgesia, particularly COX-2 inhibitors, for patients with AERD. Based on these findings, a SOP including a test dose protocol, was developed to provide clear guidance on prescribing guidance. A follow-up survey was conducted after implementation to reassess practitioner confidence.</p><p><strong>Results: </strong>Forty-four practitioners completed the initial survey; Nineteen (43%) felt comfortable managing pain in AERD, however only six (13.6%) were confident prescribing a COX-2 inhibitor for these patients. Following SOP implementation, seventeen practitioners were re-audited; sixteen (94.1%) found the SOP helpful in their decision making, and fourteen (82.4%) felt confident prescribing COX-2 inhibitors, reflecting an absolute increase of 68.8 percentage points in prescriber confidence.</p><p><strong>Discussion: </strong>This project demonstrates low confidence among practitioners in prescribing COX-2 inhibitors for patients with AERD. SOP implementation was reported to be helpful in decision-making and was associated with improved self-reported confidence, however differences between pre- and post-SOP survey groups warrant cautious interpretation. Clear prescribing guidance, including a test dose protocol may help address knowledge gaps and optimise pain management in this challenging patient population. However, effects on prescribing behaviour and patient outcomes remain to be established. We hope this small single centre implementation project will encourage other centres to develop and evaluate similar SOPs more systematically.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1854011"},"PeriodicalIF":3.4,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cpg boosts peptide-based oral immunotherapy in mice with peanut allergy.","authors":"Fang Liu, Jun-Hui Yang, Lei Han, Qiao Liu, Yang-Peng Wu, Yang-Dong Wu, Shu-Wang Peng, Xiong-Jun Peng, Ping-Chang Yang, Gui-Xiang Tian","doi":"10.3389/falgy.2026.1788819","DOIUrl":"10.3389/falgy.2026.1788819","url":null,"abstract":"<p><strong>Background: </strong>Effective therapies for peanut allergy (PA) remain limited. Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) have emerged as promising adjuvants for allergen-specific immunotherapy (AIT). This study aimed to evaluate whether a liposomal delivery system co-encapsulating peanut extract and CpG enhances therapeutic efficacy in a murine PA model and to elucidate the underlying immunoregulatory mechanisms.</p><p><strong>Methods: </strong>A murine PA model was established using peanut extract. Liposomes were formulated to carry peanut extract alone (LipP), CpG alone (LipC), both (LipCP), or were empty (LipE). PA mice received daily gavage of these formulations for two weeks. Clinical symptoms, antibody profiles, intestinal mediator release, and regulatory immune cell populations were assessed.</p><p><strong>Results: </strong>PA mice exhibited severe anaphylaxis, including a 6.0-fold increase in diarrhea incidence (Cohen's d = 8.21, 95% CI: 5.14-11.28) and a 2.3 °C median core temperature decrease (Cohen's d = 7.94, 95% CI: 4.89-10.99) compared to naive controls (NC). LipCP treatment substantially reduced PA severity: diarrhea incidence decreased by 89% (Cohen's d = 7.86, 95% CI: 4.78-10.94), core temperature reduction was abolished, serum IgE decreased by 78% (Cohen's d = 6.58, 95% CI: 3.85-9.31), and IgG2a/IgG2c levels were restored. LipCP also suppressed intestinal mast cell and eosinophil activation and increased intestinal B10 cell frequency by 3.1-fold (Cohen's d = 6.27, 95% CI: 3.64-8.90) and Tr1 cell frequency by 4.2-fold (Cohen's d = 7.15, 95% CI: 4.21-10.09). In contrast, LipP, LipC, or LipE showed only modest, non-significant effects.</p><p><strong>Conclusions: </strong>Liposomal co-delivery of peanut extract and CpG effectively suppresses peanut allergy in mice by restoring B10 cell and Tr1 cell-mediated immune tolerance. This approach warrants further investigation for clinical translation.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1788819"},"PeriodicalIF":3.4,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13329794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, propagation and characterization of human somatic cell-derived bronchial organoids as model system for airway diseases - A practical guide.","authors":"Laura Kühl, Ariana Carvalho, Nicole Löwer, Sarah Miethe, Kim Pauck, Katrin Roth, Nele von Daacke, Pauline Graichen, Eva Müßig, Emma Huy, Anne Mende, Annika Block, Melanie Bachl, Jan Henrik Pflugmacher, Paul Dechert, Daniel P Potaczek, Atefeh Sadeghi Shermeh, Holger Garn","doi":"10.3389/falgy.2026.1811482","DOIUrl":"10.3389/falgy.2026.1811482","url":null,"abstract":"<p><p>Human bronchial organoids represent a highly advanced 3D cell culture model system that reflects complex features of the airway epithelium, including structure, developmental aspects, tissue-specific functions and heterogeneous cell-cell interactions. Thus, they serve as an ideal model to study physiological differentiation and activation processes of the bronchial epithelial cells, as well as pathophysiological mechanisms of lower airway diseases. We have established, refined and validated a series of protocols for the generation, perpetuation and characterization of human bronchial lung organoids based on somatic cells derived from surgical lung tissue samples as well as from primary bronchial epithelial cells which may be obtained from healthy and diseased donors. Such organoids are cultured in an extracellular matrix gel with a serum-free medium containing a precisely adjusted growth factor cocktail. This maintains the balance between the self-renewal and differentiation capacities of the local progenitor cells, allowing the long-term culture of organoids if specific splitting and dilution as well as freezing/thawing procedures are carried out regularly and appropriately. Here we provide these detailed protocols to enable researchers to apply the organoid technology and to generate highly comparable and complementary data. Furthermore, we present several examples for the detailed characterization and analysis of human bronchial organoids, such as gene-level expression analysis, covering single cell RNA sequencing, as well as imaging and metabolic activity-based assays.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1811482"},"PeriodicalIF":3.4,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148363992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular profiling of IgE sensitization to dermatophagoides allergen components: clinical correlates in a high-exposure region.","authors":"David El-Qutob, María Dolores Martos Calahorro, Ángel Ferrer Torres, Pilar Alba Jordá, Ramón López Salgueiro, Luis Ángel Navarro Seisdedos","doi":"10.3389/falgy.2026.1816355","DOIUrl":"10.3389/falgy.2026.1816355","url":null,"abstract":"<p><strong>Introduction: </strong>Respiratory allergies, mediated by IgE reactions to house dust mites (HDM), constitute a significant disease burden in Mediterranean climates. We investigated molecular sensitization profiles to <i>Dermatophagoides</i> allergens and their clinical correlations in a high-exposure region.</p><p><strong>Material and methods: </strong>This prospective multicentre study enrolled patients (5-65 years) with HDM-allergic rhinitis/asthma from the Valencian Community, Spain. Sensitization to Dermatophagoides components (Der <i>p</i> and Der f) was analysed using ALEX² microarray (positivity boundary IgE ≥0.30 kUA/L). Statistical analyses included descriptive statistics, correlation tests, and multivariate regression.</p><p><strong>Results: </strong>Der <i>p</i> 2 (92.7%), Der f 2 (92.7%), Der <i>p</i> 1 (87%), Der p 23 (83.7%), Der f 1 (82.9%), and Der p 7 (51.2%) were the most prevalent sensitization types among 118 participants (median age 29; 53% female). Overall, 36 sensitization profiles emerged, half of which were grouped into 4 dominant profiles: profile 1 (14.4%), profile 5 (13.6%), profile 11 (6.8%), and profile 2 (95.1%), all characterized by core allergens Der p 1, Der f 1, Der p 2, and Der f 2, with varying additional components (e.g., Der p 5, 7, 21, 23). Younger age predicted higher Der p 23 reactivity (<i>p</i> < 0.05), while females showed lower Der p 7/23 sensitization. Poorly controlled rhinitis (93% of cases) and asthma correlated with Der p 1/Der f 1 responses.</p><p><strong>Conclusion: </strong>The study reveals diverse HDM sensitization profiles in a Mediterranean population, highlighting the clinical relevance of both major and minor allergens. Component-resolved diagnostics may support a better understanding of the heterogeneity of HDM sensitization profiles in high-exposure regions.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1816355"},"PeriodicalIF":3.4,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13303686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148347484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and severity of concomitant atopic dermatitis in adults with asthma: a nationwide population-based registry study.","authors":"Amalie Thorsti Møller Rønnstad, Zarqa Ali, Kjell Erik Julius Håkansson, Mia-Louise Nielsen, Lea Krog Nymand, Simon Francis Thomsen, Alexander Egeberg, Charlotte Suppli Ulrik, Jacob P Thyssen","doi":"10.3389/falgy.2026.1826356","DOIUrl":"10.3389/falgy.2026.1826356","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) often coexists with asthma, but the characteristics of AD in adults with asthma are largely unknown.</p><p><strong>Objective: </strong>The objective of this work was to examine the characteristics and severity of AD in adults with asthma.</p><p><strong>Methods: </strong>This population-based registry study identified adults (18-45 years) with an inpatient or outpatient asthma diagnosis in Danish hospitals between 1 January 2000 and 31 December 2019. AD history was determined by inpatient or outpatient diagnostic codes. AD and asthma severity were assessed through patient surveys using the Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) and the Global Initiative for Asthma (GINA) 2024.</p><p><strong>Results: </strong>Among 4,126 patients (15% response rate), 5.2% had AD. Of these, 22.7% were treated with GINA Step 4-5. Patients with AD were primarily women (74.3%) with childhood-onset AD (90.7%) and asthma (82.6%, <i>p</i> < 0.001). Mean (standard deviation) PO-SCORAD was 25.4 (16.1)). Asthma severity was not correlated or associated with AD severity. AD involvement in the head-and-neck region and on hands was common (54.0%; 61.3%) and associated with higher PO-SCORAD scores (<i>p</i> < 0.05; <i>p</i> < 0.001). AD flares during asthma exacerbations were reported by 33.0% of patients (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Asthma patients with AD often have childhood onset of both conditions and mild-to-moderate AD. Clinicians should recognize that AD in high-burden skin areas is common in asthma patients.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1826356"},"PeriodicalIF":3.4,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148347481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform: a retrospective longitudinal cohort study.","authors":"Chet Tharpe, Joshua Davidson, Kayla Mardaga, Constantine Solow, Gene Kakaulin, Tracy Kruzick, Jessica Herold, Molly Snyder, Bagrat Hakobyan","doi":"10.3389/falgy.2026.1865860","DOIUrl":"10.3389/falgy.2026.1865860","url":null,"abstract":"<p><strong>Background: </strong>Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated respiratory allergy, but real-world use is limited by access and adherence. Telemedicine-enabled sublingual immunotherapy (SLIT) may address these barriers; long-term outcomes remain incompletely characterized.</p><p><strong>Methods: </strong>Retrospective longitudinal cohort study of adults receiving personalized SLIT via a telemedicine platform (2020-2025). Participants with ≥1 baseline and ≥1 follow-up after ≥12 months of treatment were included (<i>n</i> = 2,897). Outcomes included symptom severity, medication use, quality of life (QoL), adherence, and adverse events. Longitudinal changes were analyzed using mixed-effects models; asthma subgroup analyses were performed.</p><p><strong>Results: </strong>Mean age was 39.0 years, 52.7% were female, and 25.3% had asthma. Median follow-up was 20 months. Symptom severity decreased, with a 10.1-point reduction at 6 months and smaller subsequent declines. Clinically meaningful improvement (≥30-point reduction) increased from 28% at 12 months to 45% at 24 months; higher baseline severity predicted earlier response (HR 2.95). Medication use declined over time (OR 2.31 per 12 months), with fewer medication categories used. QoL improvement increased from 81.4% at 12-18 months to 90.7% at 30-36 months (OR 4.68 per 12 months). Self-reported adherence was high (>90% for ≥20 days/month), and discontinuation was uncommon. Adverse events were infrequent and predominantly mild (Grade I: 11.7%); no anaphylaxis or eosinophilic esophagitis was reported. Among patients with asthma, longer treatment duration was associated with improved control, reduced inhaler use, and improved QoL.</p><p><strong>Conclusions: </strong>Personalized SLIT delivered via telemedicine was associated with sustained symptom improvement, reduced medication use, high adherence, and a favorable safety profile, supporting the feasibility and scalability of this care model in routine clinical practice.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1865860"},"PeriodicalIF":3.4,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148335105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}